13 — HUTCHMED (China) Share News
0.000.00%
Last trade - 00:00- HK$22.41bn
- HK$12.56bn
- $630.20m
- 23
- 38
- 60
- 32
RCS - Hutchmed China Ltd - Phase II/III Study of Fruquintinib and Sintilimab
AnnouncementREG - Hutchmed China Ltd - Adoption of the 2025 Long Term Incentive Plan
AnnouncementREG - Hutchmed China Ltd - Vesting of awards under Long Term Incentive Plan
AnnouncementREG - Hutchmed China Ltd - Notice of Extraordinary General Meeting
AnnouncementRCS - Hutchmed China Ltd - Completed Enrollment of Phase II Study
AnnouncementREG - Hutchmed China Ltd - Directorate Change
AnnouncementREG - Hutchmed China Ltd - Overseas Regulatory Announcement
AnnouncementREG - Hutchmed China Ltd - Overseas Regulatory Announcement
AnnouncementREG - Hutchmed China Ltd - Notice of Results
AnnouncementREG - Hutchmed China Ltd - Overseas Regulatory Announcement
AnnouncementRCS - Hutchmed China Ltd - Full Approval for ORPATHYS in China
AnnouncementRCS - Hutchmed China Ltd - China NDA Acceptance for ORPATHYS and TAGRISSO
AnnouncementREG - Hutchmed China Ltd - US$608m Divestment of Non-Core Joint Venture
AnnouncementREG - Hutchmed China Ltd - Overseas Regulatory Announcement
AnnouncementREG - Hutchmed China Ltd - Appointment of Joint Corporate Broker
AnnouncementREG - Hutchmed China Ltd - Blocklisting Six Monthly Return
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED to Receive Milestone Payment from Takeda
AnnouncementRCS - Hutchmed China Ltd - Breakthrough Therapy Designation in China
AnnouncementRCS - Hutchmed China Ltd - HUTCHMED and Innovent Announce ELUNATE Approval
Announcement